Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.52 |
| ▸ | HTR5A | P47898 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909285 | 0.90 | SCN9A (0.51) | SCN9AHTR5AKCNQ3KCNQ2ROCK2 | |
| SCHEMBL9907514 | 0.90 | HTR5A (0.48) | SCN9AHTR5AMAP2K4CSNK2A2CSNK2B | |
| SCHEMBL9907692 | 0.89 | HTR5A (0.55) | SCN9AHTR5AMEN1KMT2AMAP2K4 | |
| SCHEMBL9909277 | 0.89 | SCN9A (0.50) | SCN9AHTR5AKCNQ3KCNQ2MAP2K4 | |
| SCHEMBL9909289 | 0.89 | MEN1 (0.45) | SCN9AHTR5AMEN1KMT2AMAP2K4 | |
| SCHEMBL9907754 | 0.88 | HTR5A (0.47) | SCN9AHTR5AMEN1KMT2AMAP2K4 | |
| SCHEMBL9909307 | 0.85 | HTR5A (0.67) | SCN9AHTR5A | |
| SCHEMBL9907704 | 0.83 | CSNK2A2 (0.54) | HTR5AMEN1KMT2AMAP2K4CSNK2A2 | |
| SCHEMBL9908001 | 0.83 | HTR5A (0.53) | SCN9AHTR5ACSNK2A2CSNK2B | |
| SCHEMBL9909286 | 0.83 | HTR5A (0.53) | SCN9AHTR5AKCNQ3KCNQ2MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| EP-2463276-B1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2014-03-12 | — | — | EP | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| WO-2011016504-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | SCN9A 412/4885HTR5A 1/4885MEN1 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.